Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

UCART123v1.2

Cell therapy (CAR-T) · Kills target cells, directed at CD123 (interleukin-3 receptor alpha) (IL3RA) · developed by Cellectis

Phase 1 Most advanced trial

CLLS Developer

1 Registered trials

What is UCART123v1.2?

UCART123v1.2 is an allogeneic engineered T-cell therapy expressing an anti-CD123 chimeric antigen receptor, designed to target CD123-expressing cells. It is studied in relapsed or refractory acute myeloid leukemia.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type: Cell therapy (CAR-T)
Targets: CD123 (interleukin-3 receptor alpha) (IL3RA) (antigen)
Mechanism: Kills target cells, directed at CD123 (interleukin-3 receptor alpha) (IL3RA)
Therapy area: Oncology
Developer: Cellectis S.A. (CLLS)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT03190278	Phase 1	Relapsed/Refractory Acute Myeloid Leukemia	Active not recruiting	CLLS

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Relapsed/Refractory Acute Myeloid Leukemia

Other drugs acting on IL3RA

Pivekimab Sunirine FDA approved Mipletamig Phase 1

More from Cellectis

Etivelcabtagene Erigedleucel Phase 1/2 Lasmecabtagene Timgedleucel Phase 1/2 UCART123 Phase 1 UCARTCS1A Phase 1

Sources

ClinicalTrials.gov NCT03190278

Updated Oct 11, 2026. Something wrong or missing? Report it on the CLLS page.

Follow CLLS, the company behind UCART123v1.2

See CLLS's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

CLLS catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z